Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment (Q33702276)

28 July 2017

title

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment (English)

1 reference

28 July 2017

Ingelman-Sundberg M

1

1 reference

28 July 2017

Oscarson M

series ordinal

2

1 reference

28 July 2017

McLellan RA

series ordinal

3

1 reference

28 July 2017

publication date

1 August 1999

1 reference

Trends in Pharmacological Sciences

28 July 2017

published in

1 reference

28 July 2017

volume

20

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

342-349

1 reference

publication type of scholarly work

28 July 2017

review article

1 reference

Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Laying the foundations for personalized medicines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Association of CYP 3 A 4 genotype with treatment-related leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Characterization of a Human GlutathioneS-Transferase μ Cluster Containing a DuplicatedGSTM1Gene that Causes Ultrarapid Enzyme Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Quick Onset of Severe Abdominal Pain After Codeine in an Ultrarapid Metabolizer of Debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The hypoalgesic effect of tramadol in relation to CYP2D6*

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The CYP2D6 Genotype and Plasma Concentrations of Mianserin Enantiomers in Relation to Therapeutic Response to Mianserin in Depressed Japanese Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Propranolol disposition in Chinese subjects of different CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Nicotine metabolism defect reduces smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

The role of cytochrome P450 monooxygenases in plant-insect interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Invasion and maintenance of a gene duplication

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Molecular cloning of a family of xenobiotic-inducible drosophilid cytochrome P450s: Evidence for involvement in host-plant allelochemical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Involvement of cytochrome P450 in host-plant utilization by Sonoran Desert Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genetic analysis of CYP2C9 polymorphism in a Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2899%2901363-2

7 January 2021

10.1016/S0165-6147(99)01363-2

Identifiers

DOI

1 reference

28 July 2017

1 reference